Target Area:
Oncology and inflammation research
DMU-212 is a rationally designed, methylated analogue of resveratrol developed to enhance metabolic stability, bioavailability, and anticancer activity.
It demonstrates antiproliferative and pro-apoptotic effects in multiple preclinical models.
Our R&D program supports custom synthesis, scalable process development, and impurity control, enabling reliable supply for preclinical and translational research.
"Aurapha’s science-driven approach to API development demonstrates how rigorous chemistry, process robustness, and regulatory readiness can translate complex molecules into reliable, scalable drug substances."